$9.57
Insights on Vir Biotechnology Inc
Revenue is up for the last 2 quarters, -12.72M → -4.09M (in $), with an average increase of 210.4% per quarter
Netprofit is up for the last 2 quarters, -194.77M → -163.41M (in $), with an average increase of 19.2% per quarter
In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 138.7%
In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 87.8%
1.78%
Downside
Day's Volatility :4.95%
Upside
3.24%
19.33%
Downside
52 Weeks Volatility :75.53%
Upside
69.67%
Period | Vir Biotechnology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -20.9% | -1.3% | 0.0% |
6 Months | -63.68% | 1.2% | 0.0% |
1 Year | -63.53% | -5.7% | -6.5% |
3 Years | -69.15% | 17.1% | -6.5% |
Market Capitalization | 1.3B |
Book Value | $12.45 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.5 |
Wall Street Target Price | 29.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -7075.86% |
Return On Assets TTM | -17.18% |
Return On Equity TTM | -31.41% |
Revenue TTM | 118.8M |
Revenue Per Share TTM | 0.89 |
Quarterly Revenue Growth YOY | -99.3% |
Gross Profit TTM | 1.0B |
EBITDA | -634.8M |
Diluted Eps TTM | -4.5 |
Quarterly Earnings Growth YOY | 0.59 |
EPS Estimate Current Year | -4.82 |
EPS Estimate Next Year | -4.31 |
EPS Estimate Current Quarter | -1.21 |
EPS Estimate Next Quarter | -1.04 |
What analysts predicted
Upside of 210.87%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 149.0K | - |
Net Income | -69.9M | - |
Net Profit Margin | -46.9K% | - |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 868.0K | ↑ 482.55% |
Net Income | -115.9M | ↑ 65.9% |
Net Profit Margin | -13.4K% | ↑ 33529.85% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 711.0K | ↓ 18.09% |
Net Income | -174.7M | ↑ 50.74% |
Net Profit Margin | -24.6K% | ↓ 11217.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 76.4M | ↑ 10640.93% |
Net Income | -298.7M | ↑ 70.98% |
Net Profit Margin | -391.09% | ↑ 24177.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 1323.46% |
Net Income | 528.6M | ↓ 276.98% |
Net Profit Margin | 48.62% | ↑ 439.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↑ 45.39% |
Net Income | 515.8M | ↓ 2.41% |
Net Profit Margin | 32.64% | ↓ 15.98% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | -42.7M | ↓ 103.47% |
Net Income | -76.5M | ↓ 114.75% |
Net Profit Margin | 179.2% | ↑ 137.03% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 371.4M | ↓ 970.13% |
Net Income | 175.3M | ↓ 329.19% |
Net Profit Margin | 47.2% | ↓ 132.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.8M | ↓ 94.13% |
Net Income | -101.6M | ↓ 157.96% |
Net Profit Margin | -466.3% | ↓ 513.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.7M | ↑ 114.38% |
Net Income | -141.0M | ↑ 38.73% |
Net Profit Margin | -301.76% | ↑ 164.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | -12.7M | ↓ 127.23% |
Net Income | -194.8M | ↑ 38.18% |
Net Profit Margin | 1.5K% | ↑ 1832.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | -4.1M | ↓ 67.79% |
Net Income | -163.4M | ↓ 16.1% |
Net Profit Margin | 4.0K% | ↑ 2456.62% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 251.6M | - |
Total Liabilities | 320.5M | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 191.6M | ↓ 23.84% |
Total Liabilities | 370.8M | ↑ 15.69% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 512.1M | ↑ 167.27% |
Total Liabilities | 88.1M | ↓ 76.23% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 918.8M | ↑ 79.42% |
Total Liabilities | 201.9M | ↑ 129.11% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 112.71% |
Total Liabilities | 522.4M | ↑ 158.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 43.38% |
Total Liabilities | 724.1M | ↑ 38.61% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↓ 9.29% |
Total Liabilities | 667.0M | ↓ 24.73% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 2.94% |
Total Liabilities | 546.1M | ↓ 18.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↑ 3.94% |
Total Liabilities | 724.1M | ↑ 32.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↓ 4.86% |
Total Liabilities | 695.1M | ↓ 4.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 15.83% |
Total Liabilities | 433.7M | ↓ 37.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 8.87% |
Total Liabilities | 369.8M | ↓ 14.72% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.4M | - |
Investing Cash Flow | -30.0M | - |
Financing Cash Flow | 271.2M | - |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -94.1M | ↑ 41.75% |
Investing Cash Flow | -60.4M | ↑ 101.51% |
Financing Cash Flow | 25.0M | ↓ 90.79% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -129.6M | ↑ 37.77% |
Investing Cash Flow | -256.2M | ↑ 323.81% |
Financing Cash Flow | 449.2M | ↑ 1698.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -190.9M | ↑ 47.29% |
Investing Cash Flow | -9.9M | ↓ 96.15% |
Financing Cash Flow | 529.5M | ↑ 17.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.6M | ↓ 75.08% |
Investing Cash Flow | -140.8M | ↑ 1327.84% |
Financing Cash Flow | 100.3M | ↓ 81.05% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 960.1M | ↑ 74.54% |
Investing Cash Flow | -272.3M | ↑ 158.4% |
Financing Cash Flow | 3.1M | ↓ 88.87% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 117.9M | ↓ 87.72% |
Investing Cash Flow | -662.6M | ↑ 143.31% |
Financing Cash Flow | 2.0M | ↓ 35.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -125.8M | ↓ 458.09% |
Investing Cash Flow | 98.1M | - |
Financing Cash Flow | 2.3M | ↑ 16.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -389.2M | ↑ 209.46% |
Investing Cash Flow | 230.3M | ↑ 134.83% |
Financing Cash Flow | 3.2M | ↑ 35.62% |
Sell
Neutral
Buy
Vir Biotechnology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Vir Biotechnology Inc | 12.28% | -63.68% | -63.53% | -69.15% | -30.88% |
![]() Moderna, Inc. | 10.77% | -38.07% | -54.62% | -47.66% | 329.19% |
![]() Regeneron Pharmaceuticals, Inc. | -2.11% | 8.61% | 7.86% | 65.47% | 118.58% |
![]() Novo Nordisk A/s | -0.67% | 27.21% | 58.01% | 196.12% | 339.58% |
![]() Seagen, Inc. | -0.71% | 8.98% | 75.48% | 18.69% | 248.26% |
![]() Vertex Pharmaceuticals Incorporated | -8.97% | 5.01% | 10.57% | 53.8% | 97.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Vir Biotechnology Inc | 6.4 | NA | NA | -4.82 | -0.31 | -0.17 | 0.0 | 12.45 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Vir Biotechnology Inc | Buy | $1.3B | -30.88% | 6.4 | 0.0% |
![]() Moderna, Inc. | Buy | $29.6B | 329.19% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 118.58% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 339.58% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 248.26% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 97.36% | 26.52 | 35.94% |
SB INVESTMENT ADVISERS (UK) LTD
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Baillie Gifford & Co Limited.
AllianceBernstein L.P.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Organization | Vir Biotechnology Inc |
Employees | 576 |
CEO | Dr. George A. Scangos Ph.D. |
Industry | Commercial Services |
Asymmetric Smart Alpha S&p 500 Etf
$9.57
-1.24%
Advisorshares Alpha Dna Equity Sentiment Etf
$9.57
-1.24%
Liberty Tripadvisor Hdg-b
$9.57
-1.24%
Tempo Automation Holdings Inc
$9.57
-1.24%
Falcon's Beyond Global Inc
$9.57
-1.24%
Jaguar Global Growth Corporation I
$9.57
-1.24%
Missfresh Ltd
$9.57
-1.24%
Shuaa Partners Acquisition Corp I
$9.57
-1.24%
Rose Hill Acquisition Corp
$9.57
-1.24%